Goldman Sachs Upgrades Eli Lilly and Co to Buy with Price Target $95.00

Brokerage firm Goldman Sachs Upgrades its rating on Eli Lilly and Co(NYSE:LLY). In a research note issued to the investors, the brokerage major Raises the price-target to $95.00 per share. The shares have been rated Buy. Previously, the analysts had a Neutral rating on the shares. The rating by Goldman Sachs was issued on Sep 27, 2016.

In a different note, On Sep 8, 2016, JP Morgan said it Upgrades its rating on Eli Lilly and Co. The shares have been rated ‘Overweight’ by the firm. On Sep 8, 2016, JP Morgan said it Maintains its rating on Eli Lilly and Co. In the research note, the firm Raises the price-target to $92.00 per share. The shares have been rated ‘Overweight’ by the firm. On Aug 2, 2016, Argus Research said it Maintains its rating on Eli Lilly and Co. In the research note, the firm Raises the price-target to $90.00 per share. The shares have been rated ‘Buy’ by the firm. On Jul 14, 2016, Jefferies said it Maintains its rating on Eli Lilly and Co. In the research note, the firm Raises the price-target to $100.00 per share. The shares have been rated ‘Buy’ by the firm.

Eli Lilly and Co (LLY) made into the market gainers list on Fridays trading session with the shares advancing 0.65% or 0.52 points. Due to strong positive momentum, the stock ended at $80.26, which is also near the day’s high of $80.65. The stock began the session at $80.1 and the volume stood at 36,22,982 shares. The 52-week high of the shares is $88.48 and the 52 week low is $67.88. The company has a current market capitalization of $88,594 M and it has 1,10,38,43,440 shares in outstanding.

Eli Lilly and Co(LLY) last announced its earnings results on Jul 26, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $5.41B. Analysts had an estimated revenue of $5.14B. Earnings per share were $0.86. Analysts had estimated an EPS of $0.85.

Several Insider Transactions has been reported to the SEC. On Aug 17, 2016, Jackson P Tai (director) purchased 5,773 shares at $80.31 per share price.Also, On Aug 1, 2016, Endowment Inc Lilly (10% owner) sold 205,000 shares at $82.94 per share price.On Jul 29, 2016, Donald A Zakrowski (Chief Accounting Officer) sold 1,213 shares at $83.16 per share price, according to the Form-4 filing with the securities and exchange commission.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.